Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genentech AVAiL Trial Results May Lower Avastin Dosing In NSCLC

Executive Summary

Findings that a lower dose of Genentech's Avastin showed a similar treatment effect on progression-free survival as a higher dose in the AVAiL trial in first-line non-small cell lung cancer could impact physician prescribing patterns for the oncologic in lung cancer

You may also be interested in...



One Cost Of Cancer: The Rising Price Of Treatment

Given the debate surrounding the country's soaring health care costs, it's no surprise that cancer medicines - and their escalating prices - are coming under attack

One Cost Of Cancer: The Rising Price Of Treatment

Given the debate surrounding the country's soaring health care costs, it's no surprise that cancer medicines - and their escalating prices - are coming under attack

One Cost Of Cancer: The Rising Price Of Treatment

Cancer therapies hit 5 percent of total drug spending for the first time in first half of 2009, Medco says

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel